Table 3.
(Statement 8.1): Prevalence rates of malignant diseases in patient cohorts with IgG4-related disease or in patient cohorts with AIP.
| Author | Patients with malignant disease and IgG4-related disease | Control cohort | Study conclusion: In IgG4-related disease, the risk of various malignant diseases … |
|---|---|---|---|
| Hirano et al.180 | 12/95 (13%) | Japan cancer registry | … is not increased. |
| Yamamoto et al.181 | 11/106 (10%) | Japan cancer registry | … is increased. |
| Asano et al.227 | 28/109 (26%) | Japan cancer registry | … is increased. |
| Wallace et al.183 | 20/125 (16%) | Matched controls, general population | … is increased. |
| Ahn et al.230 | 12/118 (10%) | General population | … is increased. |
|
Author |
Patients with malignant disease and AiP |
Control cohort |
Study conclusion: In AiP, the risk of various malignant diseases … |
| Shiokawa et al.185 | 15/108 (14%) | Matched controls, Japan cancer registry | … is increased. |
| Schneider et al.229 | 5/28 (18%) | German cancer registry | … is increased. |
| Hart et al.187 | 19/116 (16%) | Matched controls | … is not increased. |
| Lee et al.188 | 0/138 (0%) | No control group | … is not increased. |
| Inoue et al.126 | 13/235 (0%) | No control group | … is not increased. |